Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
US Is Land Of Opportunity For Zealand
The Danish group is beefing up its operations across the Atlantic as it prepares filings for dasiglucagon and glepaglutide.
Interview: Mereo All Set For Key Setrusumab Data
Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.
Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation
Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.
Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
Sun’s Ilumya Ramps Up In Skyrizi’s Shadow
Patient numbers and prescriptions in the US for Sun’s psoriasis therapy Ilumya are steadily on the rise, and the Indian firm said that the arrival of AbbVie’s rival Skyrizi hasn’t adversely impacted its formulary position.
AZ's Brilinta Patents 'Vulnerable' To Challenge In India
An Indian court has lifted restraining orders against Micro Labs, Dr Reddy’s and Natco and held that they have made a “strong credible challenge” to the validity of AstraZeneca’s patents for Brilinta in the country. The UK firm has appealed the order.
Kala Needs Big STRIDE To Get Dry Eye Drug OK
The US FDA has issued a complete response letter for KPI-121 but Kala hopes to resubmit the drug during the first half of next year backed by data from the ongoing STRIDE 3 study.
Dull Q1 for Cipla Amid Distributor 'Churn' In India
A significant shake-up of distributors in the Indian market impacted Cipla’s first-quarter earnings but the firm expects to bounce back. Biosimilars in emerging markets and opportunities in China are among the growth drivers it is banking on.
Cutbacks Rise As Indian Pharma Tightens Control On Costs
Leading Indian pharma firms are rationalizing operations and work forces to rein in costs and improve efficiency and profitability in a tough overall operating environment. Sun Pharma, which has declared an 'unwavering focus' on cost control, recently ended operations at two Indian clinical pharmacology units.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.